Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Pechala's Reports
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Conmed Corp Lowers High End Of Prior FY Revenue 2013 Guidance; Lowers High End Of Prior FY 2013 EPS Guidance To A Range Below Analysts' Estimates; Issues Q3 2013 Guidance Below Analysts' Estimates


Wednesday, 24 Jul 2013 07:00am EDT 

Conmed Corp announced that for fiscal 2013, it expects adjusted earnings per share (EPS) guidance by reducing the top end of the previous guidance range to $1.80-$1.85 from the former $1.80-$1.90 per share. This forecast contemplates the effects of the medical device tax and less favorable FX exchange rates. The Company now expects forecasted sales range to $770-$775 million from the prior $770-$780 million. For third quarter of 2013, it expects sales to approximate $184-$189 million and adjusted earnings per share (EPS) to be $0.37-$0.42. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report EPS of $1.86 and revenue of $775 million for fiscal 2013; and revenue of $195 million and EPS of $0.45 the second quarter of 2013. 

Company Quote

44.9
-1.79 -3.83%
24 Apr 2014